Other
Unrecognized tax benefits, settlements
Vertex Pharmaceuticals Unrecognized tax benefits, settlements remained flat by 0.0% to $1.58M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 56.6%, from $3.63M to $1.58M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
A decrease indicates the resolution of tax disputes, which may reduce future cash outflows or release previously reserved tax provisions.
Detailed definition
This metric represents the reduction in the liability for unrecognized tax benefits due to formal settlements reached wi...
Peer comparison
Commonly reported by large multinational corporations as part of their tax contingency disclosures.
Metric ID:
other_unrecognized_tax_benefits_decreases_resulting_from_2f523fHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.00 | $14.50M | $6.30M |
| YoY Change | — | — | -56.6% |
Range$0.00 – $14.50M
Avg YoY Growth-56.6%
Median YoY Growth-56.6%
Unrecognized tax benefits, settlements at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's unrecognized tax benefits, settlements?
- Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits, settlements of $1.58M in Q4 2025.
- How has Vertex Pharmaceuticals's unrecognized tax benefits, settlements changed year-over-year?
- Vertex Pharmaceuticals's unrecognized tax benefits, settlements decreased by 56.6% year-over-year, from $3.63M to $1.58M.
- What does unrecognized tax benefits, settlements mean?
- The decrease in tax liability resulting from finalized agreements with tax authorities.